

Cover Story
Conversation with The Cancer LetterFree
“The notion that cancer's not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.
In Brief
Clinical Roundup
NCI Trials


NCI trials for February
NCI trials for FebruaryThe National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.” - HHS (again) postpones USPSTF meeting















